US 7,321,000 B2
Ophthalmic composition containing N-acetyl-cysteine for the treatment of dry-eye syndrome
Enrico Boldrini, Pisa (Italy); Marco Fabrizio Saettone, Pisa (Italy); Patrizia Chetoni, Pisa (Italy); Susi Burgalassi, Pisa (Italy); and Boris Giannaccini, Pisa (Italy)
Assigned to Farmigea S.p.A., Pisa (Italy)
Appl. No. 10/484,241
PCT Filed Jul. 22, 2002, PCT No. PCT/IT02/00481
§ 371(c)(1), (2), (4) Date Jun. 30, 2004,
PCT Pub. No. WO03/011249, PCT Pub. Date Feb. 13, 2003.
Claims priority of application No. RM2001A0438 (IT), filed on Jul. 23, 2001.
Prior Publication US 2004/0248847 A1, Dec. 09, 2004
Int. Cl. A61K 31/195 (2006.01)
U.S. Cl. 514—566  [514/912] 8 Claims
 
1. An ophthalmic composition based on acetylcysteine for administration in eyedrops, containing from 3 to 5% by weight of N-acetyl-cysteine neutralized with from 9 to 15% by weight of base DEAE-dextrane and having a physiologically acceptable osmolarity of less than 320 mOsm/kg.